文献速递神经肿瘤

IDH野生型弥漫性星形细胞瘤伴胶质母细胞瘤分子特征(WHO IV级):单中心病例系列与综述

Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review.
PubMed 文献 · J Neurooncol · 2021-01-03

该单中心回顾性研究比较了2018至2020年手术活检/切除的6例DAG-G患者与经典IDH突变型星形细胞瘤患者的临床、分子及影像特征。DAG-G患者年龄更大(68 vs 33岁,p<0.0001),肿瘤更弥漫(p=0.02),更易表现为局灶性神经功能缺损并仅接受活检(p=0.005),总生存期显著更短(p=0.03)。建议对疑似DAG-G患者尽早活检/切除以确诊并立即启动辅助治疗。

要点

  • DAG-G患者年龄显著大于IDH突变型星形细胞瘤患者(68 vs 33岁,p<0.0001)。
  • DAG-G肿瘤更弥漫(p=0.02),更易表现为局灶性缺损并仅行活检(p=0.005)。
  • DAG-G总生存期显著更短(p=0.03),进展与预后类似胶质母细胞瘤。

核心结论

  • DAG-G患者年龄更大,肿瘤更弥漫且易伴局灶性缺损,总生存期显著更短。
  • 建议对疑似DAG-G患者尽早活检/切除确诊并立即启动辅助治疗。

研究设计与样本

  • 单中心回顾性病例系列,纳入2018至2020年接受手术活检/切除的弥漫性星形细胞瘤患者。
  • 共识别6例DAG-G患者,并与IDH突变型星形细胞瘤患者比较临床、分子及影像特征。

主要发现

  • DAG-G患者均表现为弥漫性疾病,影像为膨胀性T2高信号病灶伴轻微强化。
  • DAG-G患者平均年龄68岁,IDH突变型为33岁(p<0.0001)。
  • DAG-G肿瘤更弥漫(p=0.02),患者更易表现为局灶性缺损并仅接受活检(p=0.005)。
  • DAG-G患者总生存期显著更短(p=0.03)。

关键数值与推荐

  • cIMPACT-NOW更新3提出:WHO II/III级IDH野生型弥漫性星形细胞瘤若含TERT启动子突变、7号染色体获得/10号染色体丢失和/或EGFR扩增,应归为WHO IV级DAG-G。

临床怎么用

  • 遇到年龄较大、弥漫性肿瘤伴局灶性缺损的患者,应警惕DAG-G可能。
  • 尽早活检或切除以确认分子诊断,并立即启动辅助治疗。

局限性

  • 单中心回顾性研究,DAG-G样本量仅6例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In 2018, cIMPACT-NOW update 3 concluded that WHO grade II/III IDH-wildtype diffuse astrocytomas that contain TERT promoter mutations, chromosome 7 gain/10 loss, and/or EGFR amplification, correspond to a WHO grade IV diagnosis and should be classified as Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV (DAG-G). We present a single-institution series of patients with DAG-G and IDH-mutant astrocytomas and compare their clinical, molecular, and radiographic characteristics. METHODS: Patient data was retrospectively extracted from the EMR for all patients undergoing surgical biopsy/resection of a diffuse astrocytoma at our institution from 2018 to 2020. Clinical presentation, molecular alterations, radiographic appearance, surgery, and survival were reviewed for each patient. RESULTS: Six DAG-G patients were identified in our cohort. All patients had diffuse disease, and presented with expansile, T2 hyperintense lesions with minimal enhancement. Compared to patients with classic IDH-mutant astrocytomas, mean age for DAG-G patients was older (68 vs 33 years, p < 0.0001), tumors were more diffuse (p = 0.02), with patients more likely to present with focal deficits and receive a biopsy only (p = 0.005). Overall survival was significantly shorter for DAG-G patients (p = 0.03). CONCLUSION: Patients with DAG-G are more likely to be older than typical IDH-mutant diffuse astrocytoma patients. They are more likely to present with tumors in a diffuse pattern with focal deficits. When such patients are encountered, prompt biopsy/resection to confirm the diagnosis and immediate initiation of adjuvant therapy is recommended, as the disease progression and overall prognosis is similar to glioblastoma.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Lee D, Riestenberg RA, Haskell-Mendoza A, et al. Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review. J Neurooncol. 2021. PMID: 33389563. doi:10.1007/s11060-020-03677-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。